An Instagram reel posted in October 2026 told viewers that a Boston trial had begun reversing the ageing of human cells, and predicted a pill that could one day turn an 80-year-old body into a 40-year-old one. The trial is real. What it has shown so far is much narrower.
What was announced
On October 8, 2026, Life Biosciences, a Boston company co-founded by Harvard Medical School geneticist David Sinclair, released the first human data from its phase 1 trial of ER-100. The interim results cover three people with open-angle glaucoma, the most common form of glaucoma.
Each received a single injection of ER-100 into the eye plus a daily oral dose of the antibiotic doxycycline. Through Day 56 the treatment was well tolerated in all three, with no dose-limiting toxicities, no serious adverse events and no adverse events of special interest, the company said. Two of the three showed improvements of more than 4 decibels at 28% or more of the points tested on their visual field exams.
Life Biosciences said efficacy cannot be established from these early findings. An independent Data Safety Monitoring Board recommended moving to the next, higher dose.
How the therapy is meant to work
ER-100 is a gene therapy that carries three of the four Yamanaka factors, OCT4, SOX2 and KLF4, known together as OSK. The fourth factor, c-MYC, is left out because it is linked to tumours. Doxycycline acts as an on switch: the genes are active only while the patient takes it.
The aim is partial epigenetic reprogramming: resetting the chemical marks that control which genes are on in the eye’s retinal ganglion cells, the nerve cells damaged in glaucoma, toward a younger pattern without turning them back into stem cells. A 2020 study in Nature from Sinclair’s Harvard lab reported that OSK restored vision in mouse models of glaucoma and ageing.
The trial also includes non-arteritic anterior ischemic optic neuropathy (NAION), a sudden loss of blood flow to the optic nerve. The data released so far cover glaucoma patients only.
What the reel gets wrong
The trial is not testing “senile vision loss”, and it has not shown that human ageing can be reversed. It involved three people, one eye injection each, and eight weeks of follow-up. “No side effects” is a stronger claim than the company made; it reported no serious ones in this small group. A pill that reverses ageing throughout the body is the presenter’s personal prediction, not something any trial has tested.
Why it still matters
Current glaucoma treatments lower eye pressure to slow damage but do not restore lost nerve function. If larger trials confirm that ER-100 can improve vision safely, it would be a new kind of treatment, and the first human test of a rejuvenation approach studied for years in animals.
People with glaucoma should keep taking their prescribed treatment and ask their eye doctor whether a clinical trial is suitable for them.
Sources
- Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
- Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies – Eyewire+
- Life Bio reaches first clinical milestone for OSK therapy
- ER-100 Enters Optic Neuropathy Trial
- Ageing: cell-rejuvenating therapy administered for the first time
- Timeline of aging research
Photo: Trilochan Netralaya (CC BY-SA 4.0)
